These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 16011668)

  • 1. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
    Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
    Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
    Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
    Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease.
    Ferkolj I; Ihan A; Markovic S
    Hepatogastroenterology; 2005; 52(64):1128-33. PubMed ID: 16001645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
    Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
    de Ridder L; Escher JC; Taminiau JA
    Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
    Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL; García-Paredes J; Cruz Santamaria DM; Lana R; Ramírez Fernández E; Rodríguez Asteaga E; Díaz-Rubio M
    Rev Esp Enferm Dig; 2002 May; 94(5):269-79. PubMed ID: 12474335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
    Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
    Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease.
    Tanaka T; Takahama K; Kimura T; Mizuno T; Nagasaka M; Iwata K; Nakano H; Muramatsu M; Takazoe M
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1143-9. PubMed ID: 16824066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.